FILE PHOTO: Medical staff prepare Moderna coronavirus (COVID-19) vaccine to be administered at newly-opened mass vaccination centre in Tokyo, Japan, May 24, 2021. Carl Court/Pool via REUTERS
(Reuters) -Moderna Inc said on Monday its COVID-19 vaccine generated a strong immune response and was generally well-tolerated in children aged six to 11 years, citing interim data from a study.
The company said it planned to submit the data to U.S., European and other regulators soon.
